Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial -

Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial
Information type: Randomised controlled trials
Source: The Lancet Infectious Diseases
Specialities: Infection and infectious diseases | Paediatric and neonatal medicine | Vaccination
Summary
RCT (n=200) in Western Kenya found that serious adverse events occurred in 41.4% of children given the malaria candidate vaccine RTS,S/AS01. The authors conclude it was sufficiently well tolerated such that the patient cohort could be included in future vaccination porogrammes.
UKMi comment
A commentary highlights that this study provides promising results on the safety and immunogenicity from administering this vaccine in HIV-infected children. Assessment of the generalisability of these findings, and how they will ultimately translate in efficacy and effectiveness trials of RTS,S/AS01 populations with a high prevalence of HIV, are important next steps.
Related links: Editorial